Literature DB >> 8641932

Vascular thermal adaptation in tumors and normal tissue in rats.

B S Nah1, I B Choi, W Y Oh, J L Osborn, C W Song.   

Abstract

PURPOSE: The vascular thermal adaptation in the R3230 adenocarcinoma, skin and muscle in the legs of Fischer rats was studied. METHODS AND MATERIALS: The legs of Fischer rats bearing the R3230 AC adenocarcinoma (subcutaneously) were heated once or twice with a water bath, and the blood flow in the tumor, skin and muscle of the legs was measured with the radioactive microsphere method.
RESULTS: The blood flow in control R3230 AC tumors was 23.9 ml/100 g/min. The tumor blood flow increased about 1.5 times in 30 min and then markedly decreased upon heating at 44.5 degrees C for 90 min. In the tumors preheated 16 h earlier at 42.5 degrees C for 60 min, reheating at 44.5 degrees C increased the tumor blood flow by 2.5-fold in 30 min. Contrary to the decline in blood flow following an initial increase during the 44.5 degrees C heating without preheating, the tumor blood flow remained elevated throughout the 90 min reheating at 44.5 degrees C. These results indicated that thermal adaptation or thermotolerance developed in the tumor vasculatures after the preheating at 42.5 degrees C for 60 min. The magnitude of vascular thermal adaptation in the tumors 24 h and 48 h after the preheating, as judged from the changes in blood flow, were smaller than that 16 h after the preheating. Heating at 42.5 degrees C for 60 min induced vascular thermal adaptation also in the skin and muscle, which peaked in 48 h and 24 h, respectively, after the heating.
CONCLUSION: Heating at 42.5 degrees C for 1 h induced vascular thermal adaptation in the R3230 AC tumor, skin, and muscle of rats that peaked 16-48 h after the heating. When the tumor blood vessels were thermally adapted, the tumor blood flow increased upon heating at temperatures that would otherwise reduce the tumor blood flow. Such an increase in tumor blood flow may hinder raising the tumor temperature while it may increase tumor oxygenation.

Entities:  

Mesh:

Year:  1996        PMID: 8641932     DOI: 10.1016/s0360-3016(96)85016-4

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  THERMAL DOSE REQUIREMENT FOR TISSUE EFFECT: EXPERIMENTAL AND CLINICAL FINDINGS.

Authors:  Mark W Dewhirst; Benjamin L Viglianti; Michael Lora-Michiels; P Jack Hoopes; Margaret Hanson
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2003-06-02

Review 2.  Hypoxia-driven immunosuppression: a new reason to use thermal therapy in the treatment of cancer?

Authors:  Chen-Ting Lee; Thomas Mace; Elizabeth A Repasky
Journal:  Int J Hyperthermia       Date:  2010       Impact factor: 3.914

3.  Tumour thermotolerance, a physiological phenomenon involving vessel normalisation.

Authors:  Ruud P M Dings; Melissa L Loren; Yan Zhang; Sterling Mikkelson; Kevin H Mayo; Peter Corry; Robert J Griffin
Journal:  Int J Hyperthermia       Date:  2011-01-04       Impact factor: 3.914

Review 4.  Mild temperature hyperthermia and radiation therapy: role of tumour vascular thermotolerance and relevant physiological factors.

Authors:  Robert J Griffin; Ruud P M Dings; Azemat Jamshidi-Parsian; Chang W Song
Journal:  Int J Hyperthermia       Date:  2010       Impact factor: 3.914

5.  Gold nanoparticle hyperthermia reduces radiotherapy dose.

Authors:  James F Hainfeld; Lynn Lin; Daniel N Slatkin; F Avraham Dilmanian; Timothy M Vadas; Henry M Smilowitz
Journal:  Nanomedicine       Date:  2014-06-03       Impact factor: 5.307

Review 6.  Integrating Hyperthermia into Modern Radiation Oncology: What Evidence Is Necessary?

Authors:  Jan C Peeken; Peter Vaupel; Stephanie E Combs
Journal:  Front Oncol       Date:  2017-06-30       Impact factor: 6.244

Review 7.  Clinical Evidence for Thermometric Parameters to Guide Hyperthermia Treatment.

Authors:  Adela Ademaj; Danai P Veltsista; Pirus Ghadjar; Dietmar Marder; Eva Oberacker; Oliver J Ott; Peter Wust; Emsad Puric; Roger A Hälg; Susanne Rogers; Stephan Bodis; Rainer Fietkau; Hans Crezee; Oliver Riesterer
Journal:  Cancers (Basel)       Date:  2022-01-26       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.